Department of Paediatric Oncology, Royal Marsden Hospital, Surrey, UK.
Pediatr Blood Cancer. 2010 Apr;54(4):654-6. doi: 10.1002/pbc.22380.
Maintenance biology-based therapy following HDCT/AHSCR in pediatric brain tumors has not been tested as yet. Failure of the HDCT/AHSCR might be due to tumor-immunity dysregulation, reactivation of the angiogenic switch and other mechanisms. Angiogenesis has been shown to be reactivated following chemotherapy. The angiogenic factors engaged in this process in childhood brain tumors following HDCT/AHSCR have not been tested in the clinic. Metronomic chemotherapy has been found to be safe and angiogenesis inhibitors are currently tested in children. Other good possible candidates for clinical trials in this setting include retinoic acid and immunotherapy.
基于维持生物学的治疗在高剂量化疗/自体造血干细胞移植（HDCT/AHSCR）后在儿科脑肿瘤中尚未被测试。HDCT/AHSCR 的失败可能是由于肿瘤免疫失调、血管生成开关的重新激活和其他机制。已经表明，化疗后会重新激活血管生成。在 HDCT/AHSCR 后儿童脑肿瘤中参与这一过程的血管生成因子尚未在临床上进行测试。节拍化疗已被证明是安全的，血管生成抑制剂目前正在儿童中进行测试。其他在这种情况下可能适合临床试验的好候选者包括维甲酸和免疫疗法。
